Literature DB >> 28855355

MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma.

Marie Ennen1,2, Céline Keime1,2, Giovanni Gambi1,2, Alice Kieny1,2,3, Sebastien Coassolo1,2, Christelle Thibault-Carpentier1,2, Fanny Margerin-Schaller3, Guillaume Davidson1,2, Constance Vagne1,2, Dan Lipsker3, Irwin Davidson4,2.   

Abstract

Purpose: Understanding tumor heterogeneity is an important challenge in current cancer research. Transcription and epigenetic profiling of cultured melanoma cells have defined at least two distinct cell phenotypes characterized by distinctive gene expression signatures associated with high or low/absent expression of microphthalmia-associated transcription factor (MITF). Nevertheless, heterogeneity of cell populations and gene expression in primary human tumors is much less well characterized.Experimental Design: We performed single-cell gene expression analyses on 472 cells isolated from needle biopsies of 5 primary human melanomas, 4 superficial spreading, and one acral melanoma. The expression of MITF-high and MITF-low signature genes was assessed and compared to investigate intra- and intertumoral heterogeneity and correlated gene expression profiles.
Results: Single-cell gene expression analyses revealed varying degrees of intra- and intertumor heterogeneity conferred by the variable expression of distinct sets of genes in different tumors. Expression of MITF partially correlated with that of its known target genes, while SOX10 expression correlated best with PAX3 and ZEB2 Nevertheless, cells simultaneously expressing MITF-high and MITF-low signature genes were observed both by single-cell analyses and RNAscope.Conclusions: Single-cell analyses can be performed on limiting numbers of cells from primary human melanomas revealing their heterogeneity. Although tumors comprised variable proportions of cells with the MITF-high and MITF-low gene expression signatures characteristic of melanoma cultures, primary tumors also comprised cells expressing markers of both signatures defining a novel cell state in tumors in vivoClin Cancer Res; 23(22); 7097-107. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28855355     DOI: 10.1158/1078-0432.CCR-17-0010

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

Review 2.  Heterogeneity in Melanoma.

Authors:  Mei Fong Ng; Jacinta L Simmons; Glen M Boyle
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

Review 3.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

4.  Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.

Authors:  Jana Travnickova; Sonia Wojciechowska; Ava Khamseh; Philippe Gautier; Daniel V Brown; Thomas Lefevre; Alessandro Brombin; Ailith Ewing; Amy Capper; Michaela Spitzer; Ramile Dilshat; Colin A Semple; Marie E Mathers; James A Lister; Eiríkur Steingrimsson; Thierry Voet; Chris P Ponting; E Elizabeth Patton
Journal:  Cancer Res       Date:  2019-10-03       Impact factor: 12.701

Review 5.  Phenotype plasticity as enabler of melanoma progression and therapy resistance.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Nat Rev Cancer       Date:  2019-06-17       Impact factor: 60.716

Review 6.  Rethinking the biology of metastatic melanoma: a holistic approach.

Authors:  Hendrik Hld Vandyck; Lisa M Hillen; Francesca M Bosisio; Joost van den Oord; Axel Zur Hausen; Véronique Winnepenninckx
Journal:  Cancer Metastasis Rev       Date:  2021-04-19       Impact factor: 9.264

Review 7.  Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.

Authors:  Farzana Ahmed; Nikolas K Haass
Journal:  Front Oncol       Date:  2018-05-24       Impact factor: 6.244

Review 8.  How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.

Authors:  Anja Wessely; Theresa Steeb; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

9.  CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma.

Authors:  Pietro Berico; Max Cigrang; Guillaume Davidson; Cathy Braun; Jeremy Sandoz; Stephanie Legras; Bujamin Hektor Vokshi; Nevena Slovic; François Peyresaubes; Carlos Mario Gene Robles; Jean-Marc Egly; Emmanuel Compe; Irwin Davidson; Frederic Coin
Journal:  EMBO Rep       Date:  2021-07-23       Impact factor: 9.071

10.  A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.

Authors:  Michael P Smith; Sareena Rana; Jennifer Ferguson; Emily J Rowling; Keith T Flaherty; Jennifer A Wargo; Richard Marais; Claudia Wellbrock
Journal:  Pigment Cell Melanoma Res       Date:  2018-10-19       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.